17-Dec-2025
Sutro Biopharma Regains Nasdaq Listing Compliance
TipRanks (Wed, 17-Dec 5:02 PM ET)
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Globe Newswire (Wed, 17-Dec 4:05 PM ET)
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 16-Dec 4:05 PM ET)
Sutro Biopharma’s Promising Phase 1 Study on STRO-004: A Potential Game-Changer in Cancer Treatment
TipRanks (Sun, 14-Dec 11:39 AM ET)
Sutro Biopharma Advances STRO-004 with First Patients Dosed in Pioneering Phase 1 Study
Market Chameleon (Thu, 4-Dec 5:03 AM ET)
Globe Newswire (Wed, 3-Dec 8:00 AM ET)
Sutro Biopharma Announces 1-for-10 Reverse Stock Split
Globe Newswire (Mon, 1-Dec 8:00 AM ET)
Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day
Globe Newswire (Wed, 12-Nov 10:00 AM ET)
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
Globe Newswire (Thu, 6-Nov 4:30 PM ET)
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
Globe Newswire (Wed, 5-Nov 4:05 PM ET)
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Sutro Biopharma trades on the NASDAQ stock market under the symbol STRO.
As of December 17, 2025, STRO stock price declined to $9.13 with 86,207 million shares trading.
STRO has a beta of 3.78, meaning it tends to be more sensitive to market movements. STRO has a correlation of 0.31 to the broad based SPY ETF.
STRO has a market cap of $77.73 million. This is considered a Micro Cap stock.
Last quarter Sutro Biopharma reported $10 million in Revenue and -$.67 earnings per share. This beat revenue expectation by $887,492 and missed earnings estimates by -$.30.
In the last 3 years, STRO traded as high as $87.20 and as low as $5.23.
The top ETF exchange traded funds that STRO belongs to (by Net Assets): VTI, VXF, IBB, IWC, PRFZ.
STRO has underperformed the market in the last year with a return of -55.9%, while SPY returned +11.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in STRO shares. However, STRO has outperformed the market in the last 3 month and 2 week periods, returning +2.4% and +25.1%, while SPY returned +2.0% and -1.5%, respectively. This indicates STRO has been having a stronger performance recently.
STRO support price is $9.08 and resistance is $10.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STRO shares will trade within this expected range on the day.